Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance
This is a multi-center, prospective, observational study designed to evaluate the impact
of LV myocardial fibrosis extent assessed by CMR on LV reverse remodeling and clinical
outcomes post TEER. The target sample will be up to 125 patients enrolled to achieve 100
ev...
Age: 18 years - 66+
Gender: All
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
This study is open to adults with chronic heart failure (HF) who have a reduced left
ventricular ejection fraction (LVEF) of less than 40%. People can join the study if they
have been diagnosed with chronic HF at least 3 months before the study. The purpose of
this s...
Age: 18 years - 66+
Gender: All
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
This study is open to adults with chronic heart failure (HF) who have a reduced left
ventricular ejection fraction (LVEF) of less than 40%. People can join the study if they
have been diagnosed with chronic HF at least 3 months before the study. The purpose of
this s...
Age: 18 years - 66+
Gender: All
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
This real-world, international registry aims to evaluate the current experience with
sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease
(ACHD) patients by investigating the prescription patterns, safety, tolerability, and
potential b...
Age: 18 years - 66+
Gender: All
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
This real-world, international registry aims to evaluate the current experience with
sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease
(ACHD) patients by investigating the prescription patterns, safety, tolerability, and
potential b...
Age: 18 years - 66+
Gender: All
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
This prospective, multicenter, cluster-randomized controlled study aims to evaluate the
accuracy of an investigational artificial intelligence (AI) Software as a Medical Device
(SaMD) designed to compute ejection fraction (EF) severity categories based on the
America...
Age: 18 years - 66+
Gender: All
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
This prospective, multicenter, cluster-randomized controlled study aims to evaluate the
accuracy of an investigational artificial intelligence (AI) Software as a Medical Device
(SaMD) designed to compute ejection fraction (EF) severity categories based on the
America...
Age: 18 years - 66+
Gender: All
Antithrombotic Activities of Sotagliflozin vs. Empagliflozin
The availability of Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) has dramatically
altered the management of heart failure (HF) patients, independently of their ejection
fraction and glycemic status. A meta-analysis of 57 studies comparing SGLT2-I monotherapy
v...
Age: 18 years - 66+
Gender: All
Antithrombotic Activities of Sotagliflozin Vs. Empagliflozin
The availability of Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) has dramatically
altered the management of heart failure (HF) patients, independently of their ejection
fraction and glycemic status. A meta-analysis of 57 studies comparing SGLT2-I monotherapy
v...
Age: 18 years - 66+
Gender: All
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin
(TTR) protein falls apart and forms amyloid, a sticky plaque- like substance that
accumulates in different organs in the body and can cause damage to the organ. There are
two way...
Age: 18 - 75 years
Gender: All
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin
(TTR) protein falls apart and forms amyloid, a sticky plaque- like substance that
accumulates in different organs in the body and can cause damage to the organ. There are
two way...
Age: 18 - 75 years
Gender: All
AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM
Study Design:
This is an international, multicenter, observational, non-interventional, prospective,
blinded, single-arm, two-period study, to collect patient utterances that will be
retrospectively analyzed to determine the sensitivity and UPNR of the HearO system...
Age: 22 years - 66+
Gender: All
AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM
Study Design:
This is an international, multicenter, observational, non-interventional, prospective,
blinded, single-arm, two-period study, to collect patient utterances that will be
retrospectively analyzed to determine the sensitivity and UPNR of the HearO system...
Age: 22 years - 66+
Gender: All
Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer
TIER-PC is an adaptive model of delivering palliative care that provides the right level
of care to the right patients at the right time. It represents an adaption of the Mount
Sinai PALLIATIVE CARE AT HOME (PC@H) program, which delivers home-based palliative care.
T...
Age: 18 years - 66+
Gender: All
Tier - Palliative Care for Patients with Advanced Heart Failure or Cancer
TIER-PC is an adaptive model of delivering palliative care that provides the right level
of care to the right patients at the right time. It represents an adaption of the Mount
Sinai PALLIATIVE CARE AT HOME (PC@H) program, which delivers home-based palliative care.
T...
Age: 18 years - 66+
Gender: All
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
This is a prospective, multi-center, open label, randomized control clinical trial
evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in
NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial).
The study contains of 5 arms:
...
Age: 18 years - 66+
Gender: All
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
This is a prospective, multi-center, open label, randomized control clinical trial
evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in
NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial).
The study contains of 5 arms:
...
Age: 18 years - 66+
Gender: All
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
Aortix is a circulatory support device for chronic heart failure patients on medical
management who have been hospitalized for acute decompensated heart failure (ADHF) and
have persistent congestion despite usual medical therapy.
Eligible ADHF patients with diureti...
Age: 21 years - 66+
Gender: All
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
Aortix is a circulatory support device for chronic heart failure patients on medical
management who have been hospitalized for acute decompensated heart failure (ADHF) and
have persistent congestion despite usual medical therapy.
Eligible ADHF patients with diureti...
Age: 21 years - 66+
Gender: All
Left vs Left Randomized Clinical Trial
The investigators aim to prospectively test the comparative effectiveness of His or Left
bundle branch pacing in relation to patient centered outcomes (quality of life, physical
activity, heart failure hospitalization, mortality) and comparative safety in relation to
...
Age: 18 years - 66+
Gender: All